168. Ehlers-Danlos syndrome Clinical trials / Disease details
Clinical trials : 13 / Drugs : 21 - (DrugBank : 11) / Drug target genes : 11 - Drug target pathways : 103
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05463679 (ClinicalTrials.gov) | January 2024 | 6/4/2022 | Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome. | A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome (vEDS) Confirmed With COL3A1 Mutations, Followed by an Open Label Extension (OLE) | Vascular Ehlers-Danlos Syndrome | Drug: Enzastaurin;Drug: Placebo | Aytu BioPharma, Inc. | Parexel | Suspended | 18 Years | 60 Years | All | 260 | Phase 3 | United States |
| 2 | NCT05603741 (ClinicalTrials.gov) | November 10, 2022 | 24/10/2022 | Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers | Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers | Ehlers-Danlos Syndrome;Anesthesia, Local | Drug: 0.9% Sodium Chloride Injection;Drug: Lidocaine Injection 2% | University of Calgary | Vanderbilt University Medical Center | Active, not recruiting | 18 Years | N/A | All | 155 | Phase 4 | Canada |
| 3 | NCT05432466 (ClinicalTrials.gov) | November 7, 2022 | 21/6/2022 | Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome | A Phase 3 Randomized, Double-Blind, Decentralized Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in the Treatment of Patients With COL3A1-Positive Vascular Ehlers-Danlos Syndrome | Vascular Ehlers-Danlos Syndrome | Drug: ACER-002 (celiprolol) 200 mg BID;Drug: Placebo BID | Acer Therapeutics Inc. | NULL | Recruiting | 15 Years | 64 Years | All | 150 | Phase 3 | United States |
| 4 | NCT05405257 (ClinicalTrials.gov) | May 13, 2022 | 2/6/2022 | Oxytocin for Hypermobile Ehlers-Danlos Syndrome | Oxytocin Treatment for Chronic Pain in Hypermobile Ehlers-Danlos Syndrome | Hypermobile Ehlers-Danlos Syndrome;Pain Assessment | Drug: Oxytocin;Other: Placebo | Baylor College of Medicine | NULL | Enrolling by invitation | 18 Years | 64 Years | Female | 20 | Phase 1/Phase 2 | United States |
| 5 | NCT04890431 (ClinicalTrials.gov) | June 2021 | 6/5/2021 | Impact of Oxygen Therapy on Fatigue in Patients With Hypermobile-type Ehlers-Danlos Syndrome | Impact of Oxygen Therapy on Fatigue in Patients With Hypermobile-type Ehlers-Danlos Syndrome: a Randomised Double-blind Placebo-controlled Study | Ehlers-Danlos Syndrome | Drug: Oxygen;Drug: Placebo | Hospital St. Joseph, Marseille, France | NULL | Not yet recruiting | 18 Years | N/A | All | 82 | Phase 4 | NULL |
| 6 | NCT04036305 (ClinicalTrials.gov) | July 26, 2019 | 25/7/2019 | Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers | Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers | Ehlers-Danlos Syndrome;Anesthesia, Local | Drug: 0.9% Sodium Chloride Injection;Drug: Lidocaine Injection 2%;Drug: Bupivacaine Injection 0.5% | Vanderbilt University Medical Center | University of Calgary | Enrolling by invitation | 18 Years | N/A | All | 230 | United States | |
| 7 | NCT02597361 (ClinicalTrials.gov) | January 2016 | 23/10/2015 | Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE) | Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial. | Ehlers-Danlos Syndrome, Vascular Type | Drug: Irbesartan;Drug: Placebo | Assistance Publique - Hôpitaux de Paris | Ministry of Health, France | Completed | 18 Years | 70 Years | All | 61 | Phase 3 | France |
| 8 | EUCTR2015-001065-76-FR (EUCTR) | 28/09/2015 | 08/09/2015 | N/A | N/A - ARCADE | MedDRA version: 18.0;Level: PT;Classification code 10014316;Term: Ehlers-Danlos syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders | Trade Name: IRBESARTAN Product Name: IRBESARTAN INN or Proposed INN: irbesartan | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | NULL | Not Recruiting | Female: yes Male: yes | 169 | Phase 3 | France | ||
| 9 | NCT01446783 (ClinicalTrials.gov) | September 2011 | 27/9/2011 | IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients | IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients | Ehlers-Danlos Syndrome, Classic | Drug: mecasermin;Drug: Saline | Bispebjerg Hospital | NULL | Completed | 18 Years | N/A | Both | 15 | N/A | Denmark |
| 10 | NCT01307527 (ClinicalTrials.gov) | November 2008 | 1/3/2011 | Riboflavin Corneal Crosslinking for Brittle Cornea Syndrome and Ehlers-Danlos Syndrome Type VI | Brittle Cornea Syndrome;Ehlers-Danlos Syndrome Type 6 | Drug: Riboflavin;Device: Kera-X | Hadassah Medical Organization | NULL | Enrolling by invitation | 18 Years | N/A | Both | 1 | N/A | Israel | |
| 11 | NCT00190411 (ClinicalTrials.gov) | October 2003 | 13/9/2005 | Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type | Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome | EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT;CHROMOSOME 2q31.2 DELETION SYNDROME | Drug: celiprolol;Drug: Control | Assistance Publique - Hôpitaux de Paris | Aventis Pharmaceuticals | Completed | 15 Years | 65 Years | Both | 54 | Phase 4 | France |
| 12 | NCT00001966 (ClinicalTrials.gov) | January 2000 | 18/1/2000 | Mind-Body Therapy for Pain in Ehlers-Danlos Syndrome | A Pilot Study of Mind-Body Therapy for Chronic Pain in Ehlers-Danlos Syndrome | Ehlers-Danlos Syndrome;Pain | Drug: Mind-body therapy | National Human Genome Research Institute (NHGRI) | NULL | Completed | N/A | N/A | Both | 40 | Phase 2 | United States |
| 13 | EUCTR2021-006574-23-NL (EUCTR) | 25/04/2022 | A study to investigate the efficacy, safety, and pharmacokinetics (PK) of enzastaurin for the prevention of arterial events in patients with vEDS confirmed with COL3A1 mutations | A multicenter, randomized, double-blind, placebo-controlled study of enzastaurin for the prevention of arterial events in patients with vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations, followed by an open label extension (OLE) - PREVEnt (Prevention of Rupture with Enzastaurin in Vascular Ehlers-Danlos Syndrome Trial) | vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations MedDRA version: 20.0;Level: PT;Classification code 10014316;Term: Ehlers-Danlos syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Enzastaurin Product Code: AR101 INN or Proposed INN: Enzastaurin Other descriptive name: ENZASTAURIN HYDROCHLORIDE | Aytu BioPharma, Inc. | NULL | NA | Female: yes Male: yes | 260 | Phase 3 | France;United States;Belgium;Netherlands;United Kingdom;Sweden |